In the context of a major COVID-19 health crisis, very high tensions on the supply of critical medicines have emerged. These medicines are essential for Covid-19 patients hospitalised in resuscitation in particular, but also for other patients affected by heavy resuscitation or requiring anaesthesia. They are hardly substitutable. Also, as of March 2020, the teams of the CHU de LILLE and those of other CHUs in France were asked by the Ministry of Health and the National Agency for the Safety of Medicines and Health Products, to prepare to produce in-house within the PUI some of these critical drugs in order to limit the risks of stock shortages and to help restore national hospital capacities in times of health crisis. The Institute of Pharmacy of the CHU, in connection with the Faculty of Pharmacy of Lille and the network of French and European hospital-university pharmacies, has studied this hypothesis and validated its technical feasibility. Clearly, it is possible to re-manufacture some of these drugs on the site of the CHU in Lille, in conditions of safety and quality allowing their hospital use. To achieve this goal, specific facilities and equipment are needed. It is the scenario of a purchase of a production and packaging automaton that has been chosen.